Shareholder update

RNS Number : 6741Q
Allergy Therapeutics PLC
04 September 2014
 



4 September 2014

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Shareholder update

 

Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2014 on the 4 September 2014. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

 

Balance Sheet as at 31 March 2014

 


£ '000

Total Non-Current Assets

14,426

Total Current Assets

18,219

Total Current Liabilities

(5,339)

Total Non-Current Liabilities

(6,436)

Total Equity

20,870

 

Consolidated Income Statement for the 6 months ended 31 March 2014

 


£'000

Revenue

27,426

Profit after tax for the period

  5,503

 

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2013.

 

-Ends-

 

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer


Ian Postlethwaite, Finance Director


www.allergytherapeutics.com






Peel Hunt LLP

+44 (0) 20 7418 8900

James Steel / Clare Terlouw






FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Victoria Foster Mitchell / Mo Noonan


 

 

Notes to editors

 

About Allergy Therapeutics

 

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business with expected revenue of £45.7million, before milestones and rebates and supported by a foreign exchange benefit of £2.3million, an increase of 14% on the previous year (2013:£39.9milllion) achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUBPBUPCGMP
UK 100

Latest directors dealings